| Added by | JPPOUGET |
|---|---|
| Group name | EquipeJPP |
| Item Type | Journal Article |
| Title | Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease |
| Creator | Bolla et al. |
| Author | Michel Bolla |
| Author | Anouk Neven |
| Author | Philippe Maingon |
| Author | Christian Carrie |
| Author | Ana Boladeras |
| Author | Demetrios Andreopoulos |
| Author | Antoine Engelen |
| Author | Santhanam Sundar |
| Author | Elzbieta M. van der Steen-Banasik |
| Author | John Armstrong |
| Author | Karine Peignaux-Casasnovas |
| Author | Jihane Boustani |
| Author | Fernanda G. Herrera |
| Author | Bradley R. Pieters |
| Author | Annerie Slot |
| Author | Amit Bahl |
| Author | Christopher D. Scrase |
| Author | David Azria |
| Author | Jan Jansa |
| Author | Joe M. O'Sullivan |
| Author | Alphonsus C. M. Van Den Bergh |
| Author | Laurence Collette |
| Abstract | PURPOSE: The European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (EFS, Phoenix) and clinical disease-free survival (DFS) of intermediate- and high-risk localized prostatic carcinoma, treated by external-beam radiotherapy (EBRT) at 70-78 Gy. We report the long-term results in intermediate-risk patients treated with 74 or 78 Gy EBRT, as per current guidelines. PATIENT AND METHODS: Of 819 patients randomly assigned between EBRT or EBRT plus AS started on day 1 of EBRT, 481 entered with intermediate risk (International Union Against Cancer TNM 1997 cT1b-c or T2a with prostate-specific antigen (PSA) ? 10 ng/mL or Gleason ? 7 and PSA ? 20 ng/mL, N0M0) and had EBRT planned at 74 (342 patients, 71.1%) or 78 Gy (139 patients, 28.9%). We report the trial primary end point EFS, DFS, distant metastasis-free survival (DMFS), and overall survival (OS) by intention-to-treat stratified by EBRT dose at two-sided ? = 5%. RESULTS: At a median follow-up of 12.2 years, 92 of 245 patients and 132 of 236 had EFS events in the EBRT plus AS and EBRT arm, respectively, mostly PSA relapse (48.7%) or death (45.1%). EBRT plus AS improved EFS and DFS (hazard ratio [HR] = 0.53; CI, 0.41 to 0.70; P < .001 and HR = 0.67; CI, 0.49 to 0.90; P = .008). At 10 years, DMFS was 79.3% (CI, 73.4 to 84.0) with EBRT plus AS and 72.7% (CI, 66.2 to 78.2) with EBRT (HR = 0.74; CI, 0.53 to 1.02; P = .065). With 140 deaths (EBRT plus AS: 64; EBRT: 76), 10-year OS was 80.0% (CI, 74.1 to 84.7) with EBRT plus AS and 74.3% (CI, 67.8 to 79.7) with EBRT, but not statistically significantly different (HR = 0.74; CI, 0.53 to 1.04; P = .082). CONCLUSION: Six months of concomitant and adjuvant AS statistically significantly improves EFS and DFS in intermediate-risk prostatic carcinoma, treated by irradiation at 74 or 78 Gy. The effects on OS and DMFS did not reach statistical significance. |
| Publication | Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology |
| Volume | 39 |
| Issue | 27 |
| Pages | 3022-3033 |
| Date | 2021-09-20 |
| Journal Abbr | J Clin Oncol |
| Language | eng |
| DOI | 10.1200/JCO.21.00855 |
| ISSN | 1527-7755 |
| Short Title | Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer |
| Library Catalog | PubMed |
| Extra | Number: 27 PMID: 34310202 |
| Tags | Adult, Aged, Aged, 80 and over, Androgen Antagonists, clinic, Humans, Male, Middle Aged, Prostatic Neoplasms, Radiation Dosage, Risk Factors, Time Factors |
| Date Added | 2023/11/23 - 12:48:42 |
| Date Modified | 2024/12/15 - 11:25:27 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
